Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion type Assertion NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_head.
- NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_provenance.
- NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion evidence source_evidence_literature NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_provenance.
- NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion SIO_000772 17768113 NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_provenance.
- NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion wasDerivedFrom befree-20150227 NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_provenance.
- NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion wasGeneratedBy ECO_0000203 NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_provenance.